Cancer Emergencies · Patient & Caregiver Guide
Immunotherapy-Related Emergencies
Immune checkpoint inhibitor complications can occur during treatment or after it stops. Tell emergency staff about past immunotherapy even if the last dose was months ago.
Educational information cannot replace emergency assessment. Hospital treatments below describe clinician decisions, not medicines or procedures to perform yourself. Follow your treating team’s personalised emergency plan.
What is this emergency?
Checkpoint inhibitors help the immune system attack cancer but can also cause inflammation in healthy organs. These immune-related adverse events range from mild to life-threatening and may affect several organs together.
Why does it happen?
Inflammation can involve the lungs (pneumonitis), bowel (colitis), liver (hepatitis), heart (myocarditis), nerves, muscles or hormone-producing glands. Hypophysitis affects the pituitary gland; adrenal insufficiency can progress to adrenal crisis. Insulin deficiency can cause diabetic ketoacidosis.
Who is at risk?
Anyone receiving a checkpoint inhibitor can be affected, including after treatment has stopped. Combination regimens may increase risk. Previous autoimmune disease or earlier toxicity influences assessment, but the absence of these factors does not exclude a serious event.
Early symptoms
New cough, diarrhea, rash, unusual fatigue, headache, dizziness, weakness, thirst or frequent urination needs prompt reporting. Liver or endocrine toxicity may first appear on blood tests rather than through obvious symptoms.
Emergency warning signs
Breathlessness, chest pain, palpitations, fainting, severe diarrhea, bloody stool, jaundice, confusion, severe headache, drooping eyelids, swallowing difficulty or rapidly progressive weakness needs urgent assessment. Vomiting with severe weakness, low blood pressure or collapse can indicate adrenal crisis; thirst with vomiting and rapid breathing can indicate ketoacidosis.
What should patients do immediately?
Contact the oncology team immediately for concerning symptoms and use emergency services for severe signs. Show your immunotherapy alert card or drug list. Do not receive the next infusion until the team has assessed suspected serious toxicity and explicitly advised whether to proceed.
What should patients avoid?
Do not assume symptoms are an infection, normal fatigue or cancer progression without assessment. Do not start or taper steroids yourself. If already prescribed adrenal replacement, follow your clinician's sick-day and emergency plan and never abruptly stop essential replacement hormones.
How is it diagnosed?
Tests depend on the organ involved: oxygen measurement and chest imaging; stool tests; liver tests; ECG and troponin; glucose, ketones, cortisol and other hormones; or neurological imaging and examinations. Infection and other causes are assessed in parallel. Suspected adrenal crisis must be treated without waiting for test results.
How is it treated in hospital?
Clinicians withhold immunotherapy for many significant toxicities and urgently involve relevant specialists. Corticosteroids or other immunosuppressive medicines may be needed, with particularly rapid action for myocarditis and severe neurological toxicity. Endocrine injury often requires hormone replacement; not every thyroid abnormality needs high-dose steroids. Restarting treatment is an individual oncology decision.
Possible complications
Complications can include respiratory failure, bowel perforation, liver injury, dangerous heart rhythms, paralysis and permanent hormone deficiency. Some events require intensive care, while others need long-term replacement treatment and monitoring.
Prevention and follow-up
Carry treatment information after therapy ends, attend blood tests and report new symptoms early. Follow taper schedules and infection-prevention advice when immunosuppressed. Obtain a written plan for hormone replacement, warning signs and whether immunotherapy can be resumed.
Frequently asked questions
Can side effects begin after the last infusion?
Yes. Delayed immune toxicity is possible; keep telling clinicians about previous checkpoint inhibitor treatment.
Does every immune side effect require permanent discontinuation?
No. Severity, organ involved and recovery determine whether treatment can safely resume.
Does this cover CAR-T reactions?
This chapter focuses on checkpoint inhibitors. CAR-T and bispecific-antibody treatment have separate emergency plans for cytokine-release syndrome and neurotoxicity; follow the treating centre’s instructions.
References
References checked on 15 October 2026. Hospital treatment follows local protocols and individual assessment.